Stephen (Steve) Letrent, Pharm.D., Ph.D.

Steve is Head of Development for TORL Biotherapeutics and 1200 Pharma. Prior roles were in leadership roles in R&D at Bristol Myers Squibb (BMS) for 6 years, Pfizer for 9 years, and Kyowa Kirin for 7 years, During his career at BMS and Pfizer, Steve chaired Development Teams in Oncology leading the early development of several novel agents for the treatment of cancer including dasatinib, antivasculars, CDK inhibitors, chemotherapeutics, and signal transduction inhibitors. At Pfizer, as VP of Clinical Development, Steve was Head of Translational Medicine for Pfizer Oncology and Development Team Leader for the Signal Transduction portfolio. At Kyowa Kirin, Steve was Head of Global Development for oncology and was also responsible for development of KHK’s innovative portfolio in immunology, nephrology, neurology and rare disease in the US and EU. 

Steve received his B.S., Pharm.D., and Ph.D. degrees at Duquesne University, the Philadelphia College of Pharmacy and Science, and the University of North Carolina at Chapel Hill. Steve completed a fellowship at University of North Carolina and Wellcome.